Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafenoquine + DHA-PQP for P. vivax Radical Cure
NCT02802501Phase 3Completed
- Sponsor
- GSK
- Start
- Apr 2018
- Primary completion
- Aug 2019
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tafenoquine in Plasmodium vivax malaria, sponsored by GSK. Started Apr 2018; status: completed.
02
Drugs
tafenoquine
03
Conditions
Plasmodium vivax malaria
Beyond the preview
Go deeper on NCT02802501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02802501.